

## EQA round: APLA2/23 - Antiphospholipid Antibodies

Deadline: 29.9.2023

Setup: Slovakia

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessedN<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

CVP = consensus of all participants

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(465) anti-β2-glycoprotein 1 screening</b>		5			5	5	100
<b>Sample A</b>		5			5	5	100
All results	CVP >>>	5	100	Positive			
<b>Sample B</b>		5			5	5	100
All results	CVP >>>	5	100	Negative			
<b>(467) anti-β2-glycoprotein 1 IgG</b>		12			12	10	83
<b>Sample A</b>		12			12	10	83
All results		2	17	Negative			
	CVP >>>	10	83	Positive			
<b>Sample B</b>		12			12	12	100
All results	CVP >>>	12	100	Negative			
<b>(468) anti-β2-glycoprotein 1 IgM</b>		12			12	12	100
<b>Sample A</b>		12			12	12	100
All results	CVP >>>	12	100	Negative			
<b>Sample B</b>		12			12	12	100
All results	CVP >>>	12	100	Negative			
<b>(461) anti-cardiolipin screening</b>		6			6	6	100
<b>Sample A</b>		6			6	6	100
All results	CVP >>>	6	100	Positive			
<b>Sample B</b>		6			6	6	100
All results	CVP >>>	6	100	Negative			
<b>(463) anti-cardiolipin IgG</b>		12			12	10	83
<b>Sample A</b>		12			12	10	83
All results		2	17	Negative			
	CVP >>>	10	83	Positive			
<b>Sample B</b>		12			12	12	100
All results	CVP >>>	12	100	Negative			
<b>(464) anti-cardiolipin IgM</b>		12			12	12	100
<b>Sample A</b>		12			12	12	100
All results	CVP >>>	12	100	Negative			
<b>Sample B</b>		12			12	12	100
All results	CVP >>>	12	100	Negative			